Citadel Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-520,560
| Closed | -$12.5M | – | 15738 |
|
|
2023
Q1 | $12.5M | Buy |
520,560
+477,796
| +1,117% | +$6M | ﹤0.01% | 2504 |
|
|
2022
Q4 | $452K | Sell |
42,764
-191,162
| -82% | -$1.54M | ﹤0.01% | 8460 |
|
|
2022
Q3 | $1.05M | Buy |
233,926
+87,503
| +60% | +$399K | ﹤0.01% | 6880 |
|
|
2022
Q2 | $586K | Buy |
146,423
+98,892
| +208% | +$469K | ﹤0.01% | 8289 |
|
|
2022
Q1 | $348K | Sell |
47,531
-115,805
| -71% | -$693K | ﹤0.01% | 10254 |
|
|
2021
Q4 | $918K | Buy |
163,336
+22,121
| +16% | +$140K | ﹤0.01% | 8161 |
|
|
2021
Q3 | $904K | Sell |
141,215
-32,499
| -19% | -$209K | ﹤0.01% | 8419 |
|
|
2021
Q2 | $1.46M | Buy |
173,714
+21,807
| +14% | +$176K | ﹤0.01% | 7375 |
|
|
2021
Q1 | $1.59M | Buy |
151,907
+121,012
| +392% | +$1.7M | ﹤0.01% | 6951 |
|
|
2020
Q4 | $523K | Sell |
30,895
-31,179
| -50% | -$467K | ﹤0.01% | 8071 |
|
|
2020
Q3 | $796K | Buy |
62,074
+29,645
| +91% | +$374K | ﹤0.01% | 6434 |
|
|
2020
Q2 | $458K | Buy |
+32,429
| New | +$409K | ﹤0.01% | 7250 |
|
|
2019
Q2 | – | Sell |
-16,864
| Closed | -$39K | – | 10074 |
|
|
2019
Q1 | $39K | Buy |
+16,864
| New | +$39.6K | ﹤0.01% | 8915 |
|
Other funds holding PRVB
Citadel Advisors's PRVB Position: Q2 2023 in Review
Citadel Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 520,560 shares — an estimated $12.5M sold.
Citadel Advisors first reported a position in PRVB in Q1 2019 and held it in 13 quarters. The position peaked at $12.5M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Citadel Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 520,560 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $12.5M.
- Citadel Advisors first reported a position in Provention Bio, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
- Citadel Advisors's Provention Bio, Inc. Common Stock position peaked at $12.5M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.